WHO ICTRP trial
Intravenous Administration of BIIB093 (Glibenclamide) in the Treatment of Severe…
NCT04950972 · NIH Clinical Trials · Recruiting
Key facts
| Trial ID | NCT04950972 |
|---|---|
| Public title | Intravenous Administration of BIIB093 (Glibenclamide) in the Treatment of Severe Cerebral Edema After Massive Cerebral Infarction |
| Scientific title | A Randomized, Double-blind, Placebo-controlled, Parallelist, Multicenter, Phase III Study Evaluating the Efficacy and Safety of Intravenous Administration of BIIB093 (Glibenburide) in the Treatment of Severe Cerebral Edema After Massive Cerebral Infarction |
| Primary sponsor | Peking University Third Hospital |
| Secondary sponsors | Beijing Tiantan Hospital |
| Registry | NIH Clinical Trials |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | Phase 3 |
| Countries | China |
| Conditions | Large Hemispheric Infarction (LHI) |
| Interventions | Drug: BIIB093;Drug: placebo |
| Registration date | Jun 27, 2021 |
| Target size | 743 |
| Secondary IDs | D2020096 |
| Registry page | clinicaltrials.gov |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: